Abstract
Water-soluble derivatives of camptothecin, an active topoisomerase I inhibitor, have shown a broad spectrum of activity against human tumors. Early clinical trials with the water-soluble sodium salt of camptothecin were hindered by significant cystitis, gastroenteritis, and leukopenia. Furthermore, the sodium salt of camptothecin has been shown to have significantly less activity than the water-insoluble lactone form of the compound. We describe a formulation of lipid-complexed CPT (LC-CPT; particle size range 20.8–208.1 nm) that is very easy to prepare and allows for intravenous administration in vivo in clinically relevant lipid-drug ratios (12.5:1 w/w). The lipid formulation had in vitro antitumor activity similar to that of CPT formulated without lipids and displayed similar cytotoxicity against MDR-1-negative and -positive tumor cells. The biodistribution of CPT was profoundly affected by lipid complexation; free CPT achieved the greatest concentration in the pulmonary parenchyma while LC-CPT achieved the highest concentration in the gastrointestinal tract. LC-CPT had significant antitumor activity in vivo against intraperitoneal L1210 and P388 leukemia and appeared to be more potent than free CPT.
Similar content being viewed by others
Author information
Authors and Affiliations
Additional information
Received: 8 November 1994/Accepted: 14 May 1995
Rights and permissions
About this article
Cite this article
Sugarman, S., Zou, Y., Wasan, K. et al. Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies. Cancer Chemother Pharmacol 37, 531–538 (1996). https://doi.org/10.1007/s002800050425
Issue Date:
DOI: https://doi.org/10.1007/s002800050425